electroCore is a Rockaway, New Jersey-based publicly listed medical device company (NASDAQ: ECOR) developing non-invasive vagus nerve stimulation (nVNS) therapy through its gammaCore device. The gammaCore is a handheld, FDA-cleared device that patients apply to the neck to self-administer transcutaneous electrical stimulation of the vagus nerve for the acute and preventive treatment of migraine and cluster headache.

The device received FDA clearance for acute treatment of episodic cluster headache in 2018, making it the first FDA-cleared nVNS device, and was subsequently cleared for migraine prevention and acute migraine treatment. The gammaCore generates a proprietary waveform delivered through the skin of the neck over the carotid sheath, where the vagus nerve is accessible without implantation.

electroCore has expanded research into additional indications including COVID-19 respiratory complications, post-acute sequelae of COVID-19 (PASC), and Parkinson's disease. The company partners with the US Department of Defense and VA for headache applications in military populations.